Long-term study of odevixibat in Alagille syndrome
Part of Digestive system, Genetic & congenital, Heart & circulation clinical trials.
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have been diagnosed with Alagille syndrome.
- You or your child must be taking odevixibat (Bylvay) now, or about to start it.
- You or your child cannot be in another research study that tests odevixibat or any other treatment for Alagille syndrome.
- You or your child cannot have a medical reason that makes odevixibat unsafe (like an allergy).
- You or your child cannot have had a liver transplant already.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
This study follows women with a genetic condition called X-linked adrenoleukodystrophy (ALD) over time to see how the disease progresses. It includes annual check-ups and MRI scans of the brain and spinal cord to monitor changes.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
Hear when a new Alagille Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.